FindTrial
Sign In

Application of HPV DNA primary screening strategy in postmenopausal women and analysis of influencing factors: a cross-sectional study.

Application of HPV DNA primary screening strategy in postmenopausal women and analysis of influencing factors: a cross-sectional study.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400094350
Enrollment
Unknown
Registered
2024-12-20
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical lesions

Interventions

Observation group:None

Sponsors

Chengdu Women and Children's Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Postmenopausal women who participated in the cervical cancer screening project with HPV DNA as the primary screening in 23 districts (cities) and counties in Chengdu from January 2022 to December 2023.

Exclusion criteria

Exclusion criteria: With incomplete medical records; those who have suffered from cervical lesions in the past;Patients with acute inflammation, malignant tumors and immune deficiency.

Design outcomes

Primary

MeasureTime frame
Positive predictive value;—

Secondary

MeasureTime frame
Age;Parity;Gravity ;Educational level;Clinical symptoms;Cervical screening history ;Family history of cancer;Routine indicators of leucorrhoea;HPV infection types;Transformation zone type ;Colposcopy impression;—

Countries

China

Contacts

Public ContactDai Qianling

Chengdu Women and Children's Central Hospital.

525790457@qq.com+86 186 2805 0755

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026